Magenta Therapeutics, Inc. (MGTA) News
Filter MGTA News Items
MGTA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest MGTA News From Around the Web
Below are the latest news stories about MAGENTA THERAPEUTICS INC that investors may wish to consider to help them evaluate MGTA as an investment opportunity.
CEO of shuttered biotech Magenta Therapeutics makes leap to Flagship startupThe former CEO of a biotech that shut down after a patient death in a clinical trial has made his way to a new startup backed by Flagship Pioneering. |
Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient DeathMagenta Therapeutics Inc (NASDAQ: MGTA) and privately-held Dianthus Therapeutics Inc have announced to merge in an all-stock transaction. The combined company will focus on advancing Dianthus' pipeline of next-generation complement inhibitors, including DNTH103, currently in Phase 1 trial. Upon completion of the merger, the combined company is expected to operate under the name Dianthus Therapeutics Inc and trade on the Nasdaq under the ticker symbol DNTH. Magenta's stockholders will own about 2 |
Magenta Therapeutics and Dianthus Therapeutics Announce Merger AgreementMerger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million from a concurrent private financing by Dianthus’ new and existing investors, which is expected to provide funding into mid-2026 Cash expected to fund lead program DNTH103 through multiple clinical dat |
Magenta Therapeutics Adopts Limited Duration Stockholder Rights PlanCAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect t |
The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta TherapeuticsBlue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics are included in this Analyst Blog. |
Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
On eve of shutdown, Cambridge biotech loses 84% of staff, including 5 execsIn the midst of exploring a sale, Magenta Therapeutics Inc. is laying off the vast majority of its staff, including five executives. |
Magenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns LoomsMagenta Therapeutics Inc (NASDAQ: MGTA) has implemented a reduction of the company's workforce by up to 56 positions, or approximately 84%, to be substantially completed by February 17, 2023. Hence, the company expects to incur estimated severance and related costs of $5.4 million by the end of February 2023. In January, following a patient death, Magenta Therapeutics paused the Phase 1/2 dose-escalation trial of its acute myeloid leukemia (AML) therapy. The fatality occurred at the Cohort 3 lev |
Magenta Therapeutics to shut down after patient deathA Cambridge biotech is set to become at least the 10th Massachusetts biotech company to shut down since the start of 2022, following the death of a patient in a clinical trial. |
Magenta Therapeutics to Explore Strategic AlternativesCAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company focused on improving stem cell transplantation, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Magenta has made the determination to halt further development of its programs and conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. As part of t |